WallStSmart

Navan, Inc. Class A Common Stock (NAVN)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Navan, Inc. Class A Common Stock generates 171% more annual revenue ($702.26M vs $258.90M). ZEPP leads profitability with a -15.5% profit margin vs -56.7%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

NAVN

Avoid

33

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 6.0Quality: 6.5
Piotroski: 4/9

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NAVNUndervalued (+22.8%)

Margin of Safety

+22.8%

Fair Value

$13.81

Current Price

$17.49

$3.68 discount

UndervaluedFair: $13.81Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NAVN1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
34.8%10/10

Revenue surging 34.8% year-over-year

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

NAVN4 concerns · Avg: 2.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-60.2%2/10

ROE of -60.2% — below average capital efficiency

Profit MarginProfitability
-56.7%1/10

Currently unprofitable

Operating MarginProfitability
-45.7%1/10

Operating margin of -45.7%

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : NAVN

The strongest argument for NAVN centers on Revenue Growth. Revenue growth of 34.8% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : NAVN

The primary concerns for NAVN are EPS Growth, Return on Equity, Profit Margin.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SOFTWARE - APPLICATION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 33/100) and 43.0% revenue growth. NAVN offers better value entry with a 22.8% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Navan, Inc. Class A Common Stock

TECHNOLOGY · SOFTWARE - APPLICATION · USA

Navan, Inc. operates an AI-powered software platform to simplify the travel and expense experience, benefiting users, customers, and suppliers. The company is headquartered in Palo Alto, California.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?